問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
施翔耀
下載
2021-07-01 - 2025-09-30
Condition/Disease
Test Drug
Participate Sites6Sites
Recruiting6Sites
Participate Sites9Sites
Terminated3Sites
2019-12-01 - 2022-12-31
Participate Sites7Sites
Recruiting7Sites
2021-07-31 - 2024-12-31
Participate Sites4Sites
Recruiting4Sites
2018-04-01 - 2020-04-01
Recruiting5Sites
未分科
2021-06-17 - 2021-12-31
The pathological diagnosis is confirmed as rectal adenocarcinoma, T3~T4, N any, M0 .The distal boundary of the tumor to the anal opening must be less than or equal to 10 cm.
PEP503
Participate Sites3Sites
Recruiting3Sites
2017-02-17 - 2020-12-17
Crohn’s Disease
Filgotinib
Participate Sites13Sites
Recruiting8Sites
Division of General Internal Medicine
Active Crohn’s Disease
Filgotinib, 100 mg and 200 mg per tablet
Participate Sites14Sites
Recruiting9Sites
全部
